Boehringer Ingelheim trials drug delivery tech for RNA-based drugs

By Flora Southey contact

- Last updated on GMT

Evox Therapeutics' COO describes the delivery tech as small "natural delivery vehicles" for drugs: GettyImages/alien185
Evox Therapeutics' COO describes the delivery tech as small "natural delivery vehicles" for drugs: GettyImages/alien185

Related tags: Protein

Boehringer Ingelheim has partnered with Evox Therapeutics to investigate the delivery of RNA-based drugs in cell-derived vesicles called exosomes.

Under the agreement, the firms will use Evox’s exosome engineering platform with targeting technology to make natural delivery nanoparticles for in vitro ​and in vivo ​research.

The collaboration aims to address diseases with high unmet medical need – in-PharmaTechnologist has previously reported​ on the difficulty of getting RNA inhibitory agents inside cells – however specific indications were not disclosed.

Upon completing the studies, BI can choose to negotiate a licence agreement to further develop RNA drug candidates using Evox’s drug delivery technology.

Exosomes

Exosomes are small, cell-derived vesicles that can be used as ‘natural delivery vehicles’ for drugs,  Evox’s COO Per Lundin told us.

“Exosomes are the body’s natural messaging system and they transport different types of biomolecules between cells and tissues in the body,” ​he said.

According to Evox, the vesicles can transport biomacromolecules – including protein, RNA therapeutics and various types of small molecule drugs – around the body.

RNA loading is done via either proprietary exogenous or endogenous loading methods, which enables Evox to work across both natural and non-natural oligonucleotides, said the firm in a statement.

Exosomes can reach difficult-to-reach target tissues, said Evox, adding that their production and purification is similar to conventional biologics manufacturing, both in terms of upstream and downstream development.

“Just like recombinant proteins (e.g. antibodies) exosomes are produced by cells in culture, meaning that the costs are comparable to conventional biologics drugs,” ​Lundin told us.

Related topics: Drug Delivery, Delivery technologies

Related news

Show more

Related products

show more

Single-Pass Tangential Flow Filtration

Single-Pass Tangential Flow Filtration

BioContinuum™ Platform - MilliporeSigma | 01-Aug-2020 | Application Note

Tangential flow filtration (TFF) is widely used in the biopharmaceutical industry for downstream processing applications. Typical TFF steps concentrate...

Flow Cytometry Services

Flow Cytometry Services

Q² Solutions | 01-Jun-2020 | Data Sheet

We are an established leader in flow cytometry services for clinical trials. Our technologies and solutions meet the growing global demand for enhanced...

Follow us

Products

View more

Webinars